AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31605793 — intervention group
Group type: EXPERIMENTAL
Intervention: NTX-010 with detectable virus at days 7 and 14
Number of subjects: 50
Study 31605793 — intervention group
Group type: EXPERIMENTAL
Intervention: NTX-010 without detectable virus at days 7 and 14
Number of subjects: 50
Study 30814669 — intervention group
Group type: COMPARATOR
Intervention: SELF group (standardised home self-training with a written training guide)
Number of subjects: 42
Study 30814669 — intervention group
Group type: EXPERIMENTAL
Intervention: REHAB group (training with an occupational therapist)
Number of subjects: 42
Study 28718346 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 4279
Study 28718346 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 4279
Study 28718346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4279
Study 28718346 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (both doses)
Number of subjects: 4279
Study 26522499 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy plus Pulmonary Rehabilitation (PR)
Number of subjects: 98
Study 26522499 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation alone
Number of subjects: 98
Study 23528840 — intervention group
Group type: EXPERIMENTAL
Intervention: The 11+ injury prevention program
Number of subjects: 36
Study 23528840 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 21370402 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by tumor resection
Number of subjects: 63
Study 21370402 — intervention group
Group type: EXPERIMENTAL
Intervention: Solely radiochemotherapy
Number of subjects: 63
Study 21370402 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and tumor resection
Number of subjects: 63
Study 21370402 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete tumor resection with postoperative radiochemotherapy
Number of subjects: 63
Study 21370402 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (all treatments)
Number of subjects: 63
Study 19135570 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg given 4 hours before D&E (Group 1)
Number of subjects: 40
Study 19135570 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline taken the night prior to D&E with dinner (Group 2)
Number of subjects: 40
Study 17970536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral water (BMW-1)
Number of subjects: 18
Study 17970536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral water (BMW-2)
Number of subjects: 18
Study 17970536 — intervention group
Group type: COMPARATOR
Intervention: Low-mineral water (LMW)
Number of subjects: 18
Study 15733356 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental education intervention (TV program, slides, brochure)
Number of subjects: 200
Study 15733356 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study 11446582 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training designed to increase right frontal alpha relative to left frontal alpha (n = 9)
Number of subjects: 18
Study 11446582 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback training designed to decrease right frontal alpha relative to left frontal alpha (n = 9)
Number of subjects: 18
Study 9611023 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative closed suction drainage using a single large Hemovac device for 2-5 days
Number of subjects: 108
Study 9611023 — intervention group
Group type: COMPARATOR
Intervention: No drainage device (control group)
Number of subjects: 108
Study 7802251 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 300 micrograms
Number of subjects: 40
Study 7802251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3071603 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (Group A: 44 patients) with 10 mg/t.i.d. of p.o. ritodrine, mean hospital stay 15 +/- 5 days
Number of subjects: 98
Study 3071603 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B: 54 patients), no ritodrine, average hospital stay 7 +/- 3 days
Number of subjects: 98
Study 3071603 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (Group A)
Number of subjects: 98
Study 3071603 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 98
Study 30300148 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (<10 mg/day, infused over 6 h per treatment)
Number of subjects: 9
Study 30300148 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alteplase
Number of subjects: 9
Study 28282844 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (anodal, 2 mA)
Number of subjects: 18
Study 28282844 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 18
Study 26177871 — intervention group
Group type: EXPERIMENTAL
Intervention: With balloon previous transurethral resection of the prostate laparoscopic radical prostatectomy
Number of subjects: 25
Study 26177871 — intervention group
Group type: EXPERIMENTAL
Intervention: No balloon previous transurethral resection of the prostate laparoscopic radical prostatectomy
Number of subjects: 25
Study 26177871 — intervention group
Group type: COMPARATOR
Intervention: Control A (surgery-naïve patients)
Number of subjects: 25
Study 26177871 — intervention group
Group type: COMPARATOR
Intervention: Control B (surgery-naïve patients)
Number of subjects: 25
Study 22850802 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intense treadmill walking (walking group)
Number of subjects: 52
Study 22850802 — intervention group
Group type: COMPARATOR
Intervention: Specific low back exercise (exercise group)
Number of subjects: 52
Study 21381465 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal coaching for teachers to improve implementation of the All Stars curriculum
Number of subjects: 48
Study 17938958 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (MA.17 trial)
Number of subjects: 3
Study 17938958 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (Austrian Breast and Colorectal Cancer Study Group 6a)
Number of subjects: 3
Study 17938958 — intervention group
Group type: COMPARATOR
Intervention: Exemestane (National Surgical Adjuvant Breast and Bowel Project B-33 trial)
Number of subjects: 3
Study 15665207 — intervention group
Group type: EXPERIMENTAL
Intervention: Decline group (single leg squats on a 25 degrees decline board)
Number of subjects: 17
Study 15665207 — intervention group
Group type: COMPARATOR
Intervention: Step group (single leg squats on a 10 cm step)
Number of subjects: 17
Study 12791655 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose chemotherapy
Number of subjects: 222
Study 12791655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy
Number of subjects: 222
Study 14677621 — intervention group
Group type: EXPERIMENTAL
Intervention: GTD 60 microg/EE 15 microg
Number of subjects: 1074
Study 14677621 — intervention group
Group type: COMPARATOR
Intervention: DSG 150 microg/EE 20 microg
Number of subjects: 1074
Study 8934042 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (estrogen)
Number of subjects: 0
Study 1880234 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg/d)
Number of subjects: 11
Study 1880234 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg/d)
Number of subjects: 11
Study 1880234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6974948 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (D series, 30 cases)
Number of subjects: 60
Study 6974948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (L series, 30 cases)
Number of subjects: 60
Study 6974948 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (Droperidol and Chlorpromazine)
Number of subjects: 60
Study 31798019 — intervention group
Group type: EXPERIMENTAL
Intervention: TCDD group (single dose of TCDD applied 21 days before 1% carrageenan solution)
Number of subjects: 0
Study 31798019 — intervention group
Group type: COMPARATOR
Intervention: C group (1% carrageenan solution without TCDD)
Number of subjects: 0
Study 28445854 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-supervised balance training for 8 weeks
Number of subjects: 40
Study 28445854 — intervention group
Group type: COMPARATOR
Intervention: Home-based balance training for 8 weeks
Number of subjects: 40
Study 25971836 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Assisted Reduction then Stop (EARS) smoking intervention
Number of subjects: 93
Study 25971836 — intervention group
Group type: COMPARATOR
Intervention: Community outreach approaches
Number of subjects: 93
Study 23535197 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 123
Study 21262061 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group using GRPACA with triaxial accelerometer
Number of subjects: 66
Study 21262061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation group using GRPACA-based linear regression models
Number of subjects: 66
Study 21262061 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific linear regression for sedentary activities
Number of subjects: 66
Study 19824078 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine (20 g daily)
Number of subjects: 55
Study 19824078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 16978993 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated angioplasty
Number of subjects: 17
Study 16978993 — intervention group
Group type: COMPARATOR
Intervention: Facilitated angioplasty with full- or half-dose thrombolysis
Number of subjects: 17
Study 16978993 — intervention group
Group type: COMPARATOR
Intervention: Primary angioplasty
Number of subjects: 17
Study 15309702 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS score (Visual Analog Scale)
Number of subjects: 0
Study 15309702 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke Activity Status Index (DASI)
Number of subjects: 0
Study 15309702 — intervention group
Group type: EXPERIMENTAL
Intervention: New York Heart Association functional class
Number of subjects: 0
Study 11713356 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled IL-5 (15 microg)
Number of subjects: 9
Study 11713356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous IL-5 (2 microg)
Number of subjects: 9
Study 11713356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9009126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Number of subjects: 10
Study 9009126 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 10
Study 9009126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8232870 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection (Omniscan)
Number of subjects: 58
Study 8232870 — intervention group
Group type: COMPARATOR
Intervention: Gadolinium-DOTA
Number of subjects: 58
Study 3318971 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (100-200 mg per day orally in two divided doses)
Number of subjects: 701
Study 3318971 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate
Number of subjects: 701
Study 3318971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 28399015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD)
Number of subjects: 25
Study 28399015 — intervention group
Group type: COMPARATOR
Intervention: Traditional Western Diet (WD)
Number of subjects: 25
Study 28647284 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 work-to-rest ratio HIIT group (SIT; n=16)
Number of subjects: 44
Study 28647284 — intervention group
Group type: EXPERIMENTAL
Intervention: 2:1 work-to-rest ratio HIIT group (LIT; n=19)
Number of subjects: 44
Study 28647284 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n=9)
Number of subjects: 44
Study 28647284 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (both SIT and LIT)
Number of subjects: 44
Study 26985607 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker counseling
Number of subjects: 209
Study 26985607 — intervention group
Group type: COMPARATOR
Intervention: Registered nurse counseling
Number of subjects: 209
Study 26985607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 209
Study 24994597 — intervention group
Group type: EXPERIMENTAL
Intervention: Melacine vaccine for 2 years
Number of subjects: 689
Study 24994597 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 689
Study 24994597 — intervention group
Group type: EXPERIMENTAL
Intervention: Melacine vaccine in HLA-A2 and/or HLA-Cw3 serotype patients (n = 178)
Number of subjects: 689
Study 24994597 — intervention group
Group type: COMPARATOR
Intervention: Observation in HLA-A2 and/or HLA-Cw3 serotype patients
Number of subjects: 689
Study 22906744 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive training program including awareness, instruction, and practice with feedback
Number of subjects: 0
Study 22906744 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice with Feedback (component of the comprehensive training)
Number of subjects: 0
Study 22906744 — intervention group
Group type: COMPARATOR
Intervention: Untrained control condition
Number of subjects: 0
Study 20385511 — intervention group
Group type: EXPERIMENTAL
Intervention: Long protocol plus NAC (group B)
Number of subjects: 76
Study 20385511 — intervention group
Group type: COMPARATOR
Intervention: Long protocol (group A)
Number of subjects: 76
Study 20385511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study 17251232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised budesonide (NB) 1,500 microg q.i.d. plus standard bronchodilator treatment (SBDT)
Number of subjects: 159
Study 17251232 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids (SC) 40 mg prednisolone plus standard bronchodilator treatment (SBDT)
Number of subjects: 159
Study 17251232 — intervention group
Group type: COMPARATOR
Intervention: Standard bronchodilator treatment (SBDT) only
Number of subjects: 159
Study 15485130 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT-based MAP (n = 5)
Number of subjects: 10
Study 15485130 — intervention group
Group type: COMPARATOR
Intervention: Behavioral-based MAP (n = 5)
Number of subjects: 10
Study 15485130 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT-based MAP
Number of subjects: 10
Study 15485130 — intervention group
Group type: COMPARATOR
Intervention: Behavioral-based MAP
Number of subjects: 10
Study 11164322 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequently Asked Questions checklist with written instructions and brochure from the Dutch Heart Foundation
Number of subjects: 103
Study 11164322 — intervention group
Group type: COMPARATOR
Intervention: Control group (brochure only)
Number of subjects: 103
Study 11164322 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequently Asked Questions checklist
Number of subjects: 103
Study 10216540 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion started at 0.05 microgram/kg/min, decreased to 0.005-0.01 microgram/kg/min for maintenance.
Number of subjects: 65
Study 10216540 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion for Group I (pulmonary blood flow increase) and Group III (mixing improvement).
Number of subjects: 65
Study 10216540 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion for Group II (systemic blood flow increase).
Number of subjects: 65
Study 10216540 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion for Group IV (left ventricular volume improvement).
Number of subjects: 65
Study 10216540 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 usage duration.
Number of subjects: 65
Study 10216540 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 related deaths.
Number of subjects: 65
Study 7638388 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament retention
Number of subjects: 48
Study 7638388 — intervention group
Group type: COMPARATOR
Intervention: Postero-stabilised prosthesis
Number of subjects: 48
Study 3070014 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training condition
Number of subjects: 0
Study 3070014 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 3070014 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training condition
Number of subjects: 0
Study 28940909 — intervention group
Group type: EXPERIMENTAL
Intervention: High ectopic burden (>10 VPCs/hour)
Number of subjects: 698
Study 28940909 — intervention group
Group type: COMPARATOR
Intervention: Low ectopic burden (≤10 VPCs/hour)
Number of subjects: 698
Study 27466244 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls prevention education
Number of subjects: 757
Study 24415665 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (5 µg/Kg body weight b.i.d.)
Number of subjects: 60
Study 24415665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22944274 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirofiban
Number of subjects: 104
Study 22944274 — intervention group
Group type: COMPARATOR
Intervention: Normal-dose tirofiban
Number of subjects: 104
Study 18838406 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercises with night splint
Number of subjects: 58
Study 18838406 — intervention group
Group type: COMPARATOR
Intervention: Eccentric exercises without night splint
Number of subjects: 58
Study 18245919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen administered prior to surgery
Number of subjects: 10
Study 18245919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ibuprofen administered)
Number of subjects: 10
Study 15728080 — intervention group
Group type: COMPARATOR
Intervention: 0.75% ropivacaine followed by 0.2% ropivacaine (group control)
Number of subjects: 60
Study 15728080 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine and 1 microg/kg clonidine followed by 0.2% ropivacaine (group cloni-bolus)
Number of subjects: 60
Study 15728080 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine and 1 microg/kg clonidine followed by 0.2% ropivacaine with 1 microg/mL clonidine (group cloni-infusion)
Number of subjects: 60
Study 15228784 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Initiative for Sexual Health intervention
Number of subjects: 0
Study 15228784 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 0
Study 11679974 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 121
Study 11679974 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 121
Study 9234663 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise dobutamine-infusion protocol (10-40 microg/kg/min, 3-min intervals)
Number of subjects: 43
Study 9234663 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dobutamine-infusion protocol (10 microg/kg/min for 12 min)
Number of subjects: 43
Study 9234663 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise dobutamine-infusion protocol
Number of subjects: 43
Study 9234663 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dobutamine-infusion protocol
Number of subjects: 43
Study 9234663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 43
Study 7900237 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with low-dose IL-2 (3 million IU/day subcutaneously for 6 days/week for 4 weeks) plus melatonin (40 mg/day orally, starting 7 days before IL-2)
Number of subjects: 60
Study 7900237 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with cisplatin (20 mg/m2) and etoposide (100 mg/m2/day intravenously for 3 days)
Number of subjects: 60
Study 7900237 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with low-dose IL-2 plus MLT
Number of subjects: 60
Study 3068951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate
Number of subjects: 0
Study 3068951 — intervention group
Group type: EXPERIMENTAL
Intervention: Homatropine
Number of subjects: 0
Study 3068951 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 3068951 — intervention group
Group type: COMPARATOR
Intervention: Cyclopentolate vs Homatropine
Number of subjects: 0
Study 3068951 — intervention group
Group type: COMPARATOR
Intervention: Homatropine vs Atropine
Number of subjects: 0
Study 3068951 — intervention group
Group type: COMPARATOR
Intervention: Atropine vs Cyclopentolate
Number of subjects: 0
Study 31621254 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture combined with dydrogesterone (10 mg orally twice a day until 12 weeks of pregnancy)
Number of subjects: 80
Study 31621254 — intervention group
Group type: COMPARATOR
Intervention: Dydrogesterone (10 mg orally twice a day until 12 weeks of pregnancy)
Number of subjects: 80
Study 31621254 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture combined with dydrogesterone
Number of subjects: 80
Study 31621254 — intervention group
Group type: COMPARATOR
Intervention: Dydrogesterone
Number of subjects: 80
Study 28179049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored behavior change techniques implemented in educational training sessions and feedback discussions in the intervention arm.
Number of subjects: 29
Study 28179049 — intervention group
Group type: COMPARATOR
Intervention: ASH training sessions provided in the control arm.
Number of subjects: 29
Study 26163200 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 28
Study 26163200 — intervention group
Group type: EXPERIMENTAL
Intervention: UR‐1505 0.5%
Number of subjects: 28
Study 26163200 — intervention group
Group type: EXPERIMENTAL
Intervention: UR‐1505 1%
Number of subjects: 28
Study 26163200 — intervention group
Group type: EXPERIMENTAL
Intervention: UR‐1505 2%
Number of subjects: 28
Study 26163200 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1%
Number of subjects: 28
Study 22964169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg twice daily plus subcutaneous IFN, 9 million units (MU) three times a week (Arm A)
Number of subjects: 101
Study 22964169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg twice daily plus subcutaneous IFN, 3 MU five times a week (Arm B)
Number of subjects: 101